Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Soluble B-Cell Maturation Antigen as a Prognostic Marker for Progression-Free Survival in Multiple Myeloma Treated with BCMA-Directed Therapies: A Systematic Review and Meta-Analysis
- Clearnote’s blood test uses AI to spot pancreatic cancer in high-risk groups
- (no title)
- (no title)
- Immuno-gene therapy for brain cancer tumors now on FDA fast track
- Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia
- FDA approves Keytruda for hard-to-treat gynecological cancers
- Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients
- FDA reviewing new iberdomide combo for hard-to-treat multiple myeloma
- (no title)